Preliminary transcriptomics studies in muscle from T2DM patients claimed to find a specific PGC1α-mediated down-regulation (26) of OXPHOS genes, concluding that this was a therapeutic-target for preventing T2DM (117). The gene discussed is PPARGC1A; the disease is type 2 diabetes mellitus.